05.06 08:58 | dpa-AFX: Gilead Announces Long-term Safety And Efficacy Data For Seladelpar In Primary Biliary Cholangitis |
05.06 08:19 | dpa-AFX: *GILEAD SCIENCES' SELADELPAR SHOWS LONG-TERM EFFICACY, SAFETY IN PRIMARY BILIARY CHOLANGITIS |
03.06 17:30 | dpa-AFX: Kite's Yescarta Pilot Study Shows Toleration In Relapsed/Refractory Central Nervous System Lymphoma |
03.06 16:27 | dpa-AFX: Kite Says Tecartus Shows Prolonged OS In Adults With Refractory B-cell Acute Lymphoblastic Leukemia |
03.06 16:17 | dpa-AFX: *KITE'S YESCARTA WELL-TOLERATED IN RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA |
03.06 16:12 | dpa-AFX: *KITE'S TECARTUS SHOWS PROLONGED OVERALL SURVIVAL IN ADULTS WITH RELAPSED/REFRACTORY B-CELL ALL |
31.05 03:14 | dpa-AFX: Gilead : Phase 3 Study Of Trodelvy In Metastatic Urothelial Cancer Fails To Meet Primary Endpoint |
18.05 15:42 | dpa-AFX: Gilead's Seladelpar Shows Major Liver Disease Progression Improvement, Itch Reduction In PBC Study |
26.04 15:02 | dpa-AFX: Gilead Sciences Says FDA OK's Updated Label Of Biktarvy To Treat Pregnant People With HIV-1 |
26.04 14:07 | dpa-AFX: *GILEAD SCIENCES: FDA APPROVES BIKTARVY(R) LABEL UPDATE WITH DATA FOR PREGNANT ADULTS WITH HIV |
25.04 23:12 | dpa-AFX: Gilead Sciences Inc. Q1 Earnings Summary |
25.04 22:57 | dpa-AFX: *GILEAD SCIENCES Q1 LOSS/SHARE $3.34 VS. PROFIT $0.80 YEAR AGO |
25.04 12:03 | dpa-AFX: Gilead Sciences Q1 24 Earnings Conference Call At 4:30 PM ET |
02.04 13:46 | dpa-AFX: Nurix Therapeutics Says Gilead Sciences Extends Ongoing Strategic Collaboration By Addl. Two Years |
02.04 13:30 | dpa-AFX: *NURIX THERAPEUTICS ANNOUNCES EXTENSION OF STRATEGIC COLLABORATION WITH GILEAD SCIENCES BY 2 YRS |
28.03 14:17 | dpa-AFX: Gilead's SNDA For Vemlidy Gets FDA Approval To Treat Chronic HBV Infection In Pediatric Patients |
28.03 13:34 | dpa-AFX: *GILEAD : FDA EXPANDS INDICATION FOR VEMLIDY TO TREAT CHRONIC HBV INFECTION IN PEDIATRIC PATIENTS AS YOUNG AS SIX |
28.03 12:34 | dpa-AFX: Gilead, Xilio Announce Exclusive License Agreement For Tumor-Activated IL-12 Program XTX301 |
28.03 12:06 | dpa-AFX: *GILEAD SCIENCES, XILIO THERAPEUTICS ANNOUNCE LICENSE AGREEMENT TO DEVELOP TUMOR-ACTIVATED IL-12 PROGRAM, XTX301 |
22.03 15:06 | dpa-AFX: Gilead Sciences Completes Acquisition Of CymaBay Therapeutics |
|